- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Potentially Undervalued Companies
U.S. Pharmaceuticals & Biotech Potentially Undervalued Companies
UPDATED Oct 26, 2023
Companies with a Value score of at least 3, ordered by Value score
425 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| AAgilent Technologies | US$104.31 | -4.7% | -23.6% | US$30.5b | US$137.62 | PE26.9x | E12.5% | 0.9% | ||
| BCRXBioCryst Pharmaceuticals | US$5.46 | -4.5% | -59.9% | US$1.0b | US$15.20 | PS3.4x | E70.0% | n/a | ||
| RGED.FRichter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt | Ft27.37 | 0% | n/a | Ft1.6t | Ft33.42 | PE14.6x | E29.3% | 4.5% | ||
| IVVDInvivyd | US$1.66 | 5.1% | -55.9% | US$181.1m | US$2.50 | PB0.6x | E63.3% | n/a | ||
| TGRN.FTong Ren Tang Technologies | HK$0.85 | 0% | n/a | HK$7.1b | HK$1.19 | PE10.5x | E4.0% | 3.1% | ||
| NBIXNeurocrine Biosciences | US$107.92 | -2.9% | -5.2% | US$10.6b | US$134.64 | PE59.7x | E33.8% | n/a | ||
| INTIInhibitor Therapeutics | US$0.051 | -4.6% | 5.5% | US$8.9m | n/a | PE0.8x | n/a | n/a | ||
| INCYIncyte | US$54.27 | -2.5% | -25.5% | US$12.2b | US$82.80 | PE33.2x | E30.9% | n/a | ||
| PMSN.FProteome Sciences | UK£0.075 | 0% | n/a | UK£17.8m | n/a | PE26x | n/a | n/a | ||
| MXDH.FMDxHealth | €0.25 | 0% | n/a | €61.4m | €1.00 | PS1.2x | E47.6% | n/a | ||
| SCCP.FSciClone Pharmaceuticals (Holdings) | HK$0.83 | 0% | n/a | HK$5.6b | HK$1.10 | PE5.5x | E1.0% | 3.9% | ||
| OPOR.FhVIVO | UK£0.15 | 0% | n/a | UK£123.9m | n/a | PS2.4x | E56.9% | n/a | ||
| SBLO.FShin Nippon Biomedical Laboratories | JPÂ¥16.97 | 0% | n/a | JPÂ¥96.8b | JPÂ¥26.65 | PE17.6x | E15.2% | 2.2% | ||
| INVV.YIndivior | UK£21.85 | -0.5% | 28.4% | UK£2.4b | UK£30.38 | PS3.2x | E40.4% | 0% | ||
| ADDL.FAddLife | kr7.94 | 0% | n/a | kr7.3b | kr17.84 | PE19x | E15.2% | 2.0% | ||
| SNPH.FSanten Pharmaceutical | JPÂ¥8.75 | 0% | 34.5% | JPÂ¥471.4b | JPÂ¥10.80 | PS1.6x | E30.9% | 2.5% | ||
| CRISCuris | US$4.05 | -12.3% | -74.5% | US$22.9m | US$152.75 | PS2.3x | E-11.0% | n/a | ||
| SNPH.YSanten Pharmaceutical | JPÂ¥8.50 | -2.5% | 24.1% | JPÂ¥471.4b | JPÂ¥10.49 | PS1.6x | E30.9% | 2.5% | ||
| RZLTRezolute | US$0.98 | 3.2% | -44.9% | US$37.9m | US$7.80 | PB0.3x | E29.1% | n/a | ||
| KRYSKrystal Biotech | US$118.01 | 7.3% | 56.1% | US$3.2b | US$151.40 | PB5.1x | E68.0% | n/a | ||
| DNLIDenali Therapeutics | US$19.28 | 2.1% | -30.6% | US$2.7b | US$52.27 | PS7.7x | E-13.3% | n/a | ||
| KRTXKaruna Therapeutics | US$167.28 | -1.9% | -24.6% | US$6.3b | US$268.24 | PS1047.9x | E55.4% | n/a | ||
| CNTBConnect Biopharma Holdings | US$1.14 | -3.0% | 31.5% | US$68.8m | US$6.00 | PB0.5x | E23.6% | n/a | ||
| PULMPulmatrix | US$1.87 | -4.1% | -44.7% | US$6.6m | US$10.00 | PB0.3x | E27.8% | n/a |